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Objectives The purpose of this study was to determine whether atrial pacing is a safe alternative to minimal (backup-only)
ventricular pacing in defibrillator recipients with impaired ventricular function.
Background The DAVID (Dual Chamber and VVI Implantable Defibrillator) trial demonstrated that dual chamber rate respon-
sive pacing as compared with ventricular backup-only pacing worsens the combined end point of mortality and
heart failure hospitalization. Although altered ventricular activation from right ventricular pacing was presumed
to be the likely cause for these maladaptive effects, this supposition is unproven.
Methods In all, 600 patients with impaired ventricular function from 29 North American sites, who required an implanted
defibrillator for primary or secondary prevention, with no clinical indication for pacing, were randomly assigned
to atrial pacing (at 70 beats/min) versus minimal ventricular pacing (at 40 beats/min) and followed up for a
mean of 2.7 years.
Results There were no significant differences between pacing arms in patients’ baseline characteristics, use of heart fail-
ure medications, and combined primary end point of time to death or heart failure hospitalization during follow-
up, with an overall incidence of 11.1%, 16.9%, and 24.6% at 1, 2, and 3 years, respectively. Similarly, the inci-
dence of atrial fibrillation, syncope, appropriate or inappropriate shocks, and quality of life measures did not
significantly differ between treatment groups.
Conclusions The effect of atrial pacing on event-free survival and quality of life was not substantially worse than, and was
likely equivalent to, backup-only ventricular pacing. Atrial pacing may be considered a “safe alternative” when
pacing is desired in defibrillator recipients, but affords no clear advantage or disadvantage over a ventricular
pacing mode that minimizes pacing altogether. (Dual Chamber and VVI Implantable Defibrillator [DAVID] Trial II;
NCT00187187) (J Am Coll Cardiol 2009;53:872–80) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.057s
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amplantable defibrillators save lives by treating life-
hreatening ventricular tachycardia or fibrillation. However,
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Manuscript received August 30, 2008; revised manuscript received October 15,
008, accepted October 21, 2008.ome patients may require bradycardia pacing in addition to
ntitachycardia therapy from their defibrillator. The
AVID (Dual Chamber and VVI Implantable Defibrilla-
or) trial demonstrated that dual chamber rate responsive
acing at 70 beats/min (DDDR-70) worsens the combined
nd point of mortality and hospitalization for heart failure
See page 881
ompared with ventricular backup-only pacing at 40 beats/
in (VVI-40) in patients with impaired ventricular function
1). Although cardiac resynchronization studies suggest that
ltered ventricular activation from right ventricular pacing
as the likely explanation for these maladaptive effects in
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March 10, 2009:872–80 The DAVID II Trialhe DAVID trial (2), this supposition is unproven. Such an
dverse outcome might occur through a variety of mecha-
isms other than ventricular dyssynchrony. These include
he increased heart rate from pacing or a sensor-driven rate
esponse, creation of a nonphysiologic atrioventricular (AV)
onduction interval during AV sequential pacing, and/or
ffects from atrial pacing itself (such as disruption of
eft-sided heart AV synchrony by right atrial stimulation)
3). Although not required for most defibrillator patients,
ddressing the most suitable modality when pacing is desired
s important because it potentially affects the future design
nd application of such therapies in this population (4),
articularly among those who are not candidates for biven-
ricular systems. Notably, only ventricular backup pacing
nd biventricular stimulation, for some heart failure pa-
ients, have thus far been safely combined with implantable
efibrillator therapy.
The purpose of this trial was to isolate the effects of the
trial pacing mode itself from those other proposed mech-
nisms for the outcome of the DAVID trial. Our specific
bjective was to determine if atrial pacing mimics the
dverse consequences of the AV sequential, rate responsive
acing observed in the DAVID trial, or whether it is a
iable and safe alternative to a mode that attempts to
inimize ventricular pacing in defibrillator recipients.
ethods
he DAVID II trial was a randomized, parallel arm,
oninferiority trial with implantable defibrillator recipients
ho had left ventricular dysfunction, comparing atrial pac-
ng at 70 beats/min (AAI-70) to minimal ventricular pacing
VVI-40). The AAI-70 pacing was selected to insure receipt
f atrial pacing for evaluation of this pacing mode at a
hysiologic but not unduly rapid rate. Eligibility criteria are
escribed in Table 1, and included patients previously
andomized in the VVI-40 arm of the DAVID trial who
ad not yet met that trial’s clinical end point. Patients
eceived defibrillators for primary or secondary prevention;
one had clinical indications for bradycardia pacing.
wenty-nine North American sites participated, most had
nrolled patients in the DAVID trial (1), and maintained
he same infrastructure for both studies.
andomization. All patients received commercially ap-
roved St. Jude Medical (St. Paul, Minnesota) dual cham-
er defibrillators (Epic or Atlas DR Family) and leads
Riata Family). The precise right-side heart lead implant
ites were not pre-specified, but were commonly in the
icinity of the right atrial appendage and ventricular apex.
mmediately after successful implantation with testing of
efibrillation efficacy, patients were randomly allocated to
radycardia support (AAI-70 or VVI-40). Antitachycardia
arameters of defibrillators were programmed as described
n the DAVID trial, using pre-specified criteria with flexi-
ility to meet the clinical needs of patients (1). Randomiza-
ion was done centrally and stratified by newly enrolled patients
l
Vsubstratified by investigational
ite, heart failure history, and im-
lantable defibrillator indication)
nd re-randomized DAVID trial
atients (substratified by heart fail-
re history). Patients were blinded
o their pacing mode and followed
p every 3 months until the com-
on termination date.
ther therapies. Patients were
equired to be taking appropriate
eart failure medications at study
ntry, and continued treatment
ith angiotensin-converting en-
yme inhibitors or receptor block-
rs, beta-blockers, digitalis, di-
retics, and spironolactone, the
itration of which was reviewed at every follow-up visit, with
he goal of achieving 50% of the target daily doses
ecommended in the Heart Failure Society of America
ractice Guidelines (5). Antiarrhythmic medications re-
uired for treatment of supraventricular arrhythmias at the
ime of randomization were maintained, as were antithrom-
otic therapies.
Occurrences of symptomatic bradycardia during follow-up
ere treated by adjustment or discontinuation of medica-
ions having such effects and, when required, by adjustment
Abbreviations
and Acronyms
AAI-70  atrial pacing at a
rate of 70 beats/min
AV  atrioventricular
DDDR-70  dual chamber
rate responsive pacing at
70 beats/min
MLHF  Minnesota Living
with Heart Failure
Questionnaire
NYHA  New York Heart
Association
VVI-40  ventricular
backup pacing at a rate of
40 beats/min
nclusion and Exclusionriteria for Study Randomization
Table 1 Inclusion and ExclusionCriteria for Study Randomization
Inclusion criteria (1 of the following):
1. Prior enrollment in and randomization to the VVI-40 treatment arm of the
DAVID trial without having met that trial’s clinical end point
2. LVEF 0.40 and 1 of the following spontaneous sustained ventricular
arrhythmias unrelated to a transient or correctable cause within the
preceding 6 weeks:
a. Cardiac arrest due to VF or VT
b. VT with syncope
c. VT with significant symptoms or systolic blood pressure 80 mm Hg
3. LVEF 0.40 with or without spontaneous ventricular arrhythmias and
EPS-inducible VT or VF within the preceding 6 weeks
4. LVEF 0.30 due to coronary artery disease and 1 month from acute
myocardial infarction and 3 months from an invasive coronary
intervention
Exclusion criteria (any of the following):
1. Permanent pacemaker
2. Symptomatic bradycardia, or PR interval 0.24 s, or second- or third-degree
atrioventricular block
3. Atrial fibrillation 6 months or of unknown duration
4. Frequent, uncontrolled supraventricular tachycardia
5. NYHA functional class IV heart failure or 3 months of optimal therapy for
NYHA functional class III heart failure
6. Awaiting cardiac transplantation
7. Prisoner or ward of the state
8. Unable to give informed consent
9. Life expectancy 1 yr
AVID Dual Chamber and VVI Implantable Defibrillator; EPS electrophysiologic study; LVEF
eft ventricular ejection fraction; NYHA  New York Heart A
T  ventricular tachycardia; VVI-40  ventricular back-upssociation; VF  ventricular fibrillation;
pacing at 40 beats/min.
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The DAVID II Trial March 10, 2009:872–80f the paced rate before addressing pacing mode. If required
or clinical indications, a change in pacing mode (a change
n the site of pacing to the alternate chamber, or to a
ultichamber pacing mode) was permitted.
nd points. The primary combined end point was time to
eath or heart failure hospitalization. Heart failure hospi-
alization was determined by an Events Committee who
eviewed all records (blinded to treatment assignment)
ertaining to hospitalization with an admitting or contrib-
tory diagnosis of heart failure. Qualifying heart failure
equired both 24-h hospitalization with clinically worsen-
ng heart failure symptoms, and at least 1 intensive treat-
ent for heart failure (intravenous diuresis, intravenous
notropic medications, or dialysis) within 24 h of admission.
econdary end points included all appropriate implantable
efibrillator therapies delivered for ventricular fibrillation or
achycardia, all inappropriate therapies for conditions unre-
ated to ventricular tachyarrhythmias (each adjudicated by
linded review of implantable defibrillator electrograms),
nd quality of life measurements. Additional end points
ncluded time to first occurrence of confirmed atrial fibril-
ation, syncope, and other hospitalization.
uality of life. General measures of quality of life were
ssessed using the Short Form 36-Item Health Survey and
he Minnesota Living with Heart Failure Questionnaire
MLHF), both of which were obtained at baseline and at
-month follow-up; the Global Rating Change and the
imple Outcome Screen, obtained at baseline and at each
ollow-up visit; and a modified Short Form-36 Health
urvey at trial completion. With the exception of the Simple
utcome Screen (administered by study personnel), sites
ere blinded to quality of life survey results, which were
elf-administered and conveyed directly to the central coor-
inating center. The Short Form-36 Health Survey is a
ommonly used general assessment of quality of life (6–8).
t consists of 36 items, providing an overall score with
ental and physical components. The MLHF has been
sed in almost all assessments of quality of life in heart
ailure studies, using 21 items particularly relevant to heart
ailure patients (9,10). The Simple Outcome Screen consists
f 2 questions designed to assess outcome after stroke (11),
ut is also useful for assessing recovery from cardiac arrest.
inally, the Short Form-36 Health Survey was substantially
odified to provide a much shorter instrument with a high
orrelation to the original Short Form-36 Health Survey
hysical summary score. An algorithm constructed theoret-
cally, that is, without attention to the actual data, to
ranslate responses from the Short Form-36 Health Survey
nto “presumed” responses to the Modified Short Form-36
ealth Survey yielded correlations of 0.94 when applied to
he baseline and 6-month Short Form-36 Health Survey
ata.
ollow-up. Patients were followed up at 3-month inter-
als. After the 6-month follow-up, alternative 3-month
isits could be conducted by telephone with remote im-
lantable defibrillator interrogation and download of pa- bameters and events and verbal assessment of the patient’s
ondition. Remote or in-person implantable defibrillator
nterrogations were also performed when patients re-
eived a shock therapy. Death, possible heart failure
ospitalization, serious complications related to the de-
ice, leads, or medications, change of pacing modality, or
ithdrawal from the study were reported within 24 hours
f discovery.
versight. The study was approved by the Institutional
eview Boards at all sites; all participants gave written
nformed consent. An independent Data and Safety Mon-
toring Board reviewed data and end points approximately
very 6 months and could recommend design changes or
arly trial termination.
tatistical design and analysis. The DAVID II trial was
esigned as a 1-sided (noninferiority) trial testing the null
ypothesis that the effect of atrial pacing, like DDDR-70 in
he DAVID trial, will worsen the combined end point of
otal mortality and heart failure hospitalization, as compared
ith ventricular backup-only pacing. Specifically, the null
ypothesis for the DAVID II trial was HO:   0.425
ears, where  is the difference between the median event-
ree survival time in the AAI arm and the VVI arm. By
omparison, in the DAVID trial, the difference in median
ime to an event between the DDDR-70 and VVI-40 arms
as   0.48 years. The alternative hypothesis was HA:
 0. That is, the effect of atrial pacing would be no worse
han VVI-40 on the combined end point.
It was planned to enroll 600 patients and follow until 200
vents had occurred. Assuming event rates similar to those
bserved in the DAVID trial (median time to the primary
nd point of 3.85 years), it was anticipated this would
equire an average follow-up of 2.5 years. A sequential
esting design was used that included a boundary for
ejecting the null and a futility boundary for not being able
o reject the null. Testing was to occur at increments of
pproximately 50 events. The number of events was chosen,
sing the Simulator of Sequential Trials in East 2000 (12),
o that the alpha level of the study (the probability of
ejecting the null, that AAI-70 is worse than VVI-40, when
t was true)  0.025. The power of the study (the proba-
ility of rejecting the null if the alternative, HA:   0, was
rue)  0.746. The sequential boundaries were chosen such
hat if AAI-70 trended superior to VVI-40, the trial would
e terminated in short order to conduct a typical 2-sided
uperiority trial, whereas if AAI-70 trended inferior to
VI-40, in particular if HO were true, the trial would be
erminated in approximately 2 years.
Differences in continuous and dichotomous variables
ere analyzed with the use of Student’s t test, the chi-square
est, or the Mann-Whitney U test. Failure-time regression
odels were used for secondary analyses of the primary end
oints, as well as for subgroup and exploratory analyses.
eneralized linear models were used to analyze the repeated
uality of life measures. Statistical significance was indicated
y p  0.05.
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March 10, 2009:872–80 The DAVID II Trialesults
opulation. Between June 2003 and February 2005, 600
atients were enrolled and 300 randomly assigned to each
acing treatment group (Fig. 1). Baseline patient character-
stics are described in Table 2. There were no significant
ifferences in these characteristics between treatment
roups, including the factors identified in the DAVID trial
s being associated with increased heart failure hospitaliza-
ion or death (1). As shown in Figure 1, a total of 49
atients changed pacing mode assignment during the
ollow-up period before reaching a primary end point.
hese included 7 patients who were reprogrammed to the
lternate single-chamber pacing mode, and 42 who were
hanged to dual chamber pacing. These changes in pacing
ode during follow-up were equally distributed between
oth treatment cohorts. In addition, after an average
ollow-up period of 1.7 years, 23 patients (a comparable
roportion from both treatment groups) were lost to follow-
p. Another 19 were withdrawn by protocol after meeting
he heart failure hospitalization end point (12 received a
iventricular defibrillator, 4 underwent heart transplanta-
239
4 no co fu
245227
QoL
300
VVI-40
300
AAI-70
R
287
11 no 6mo fu
287
6 no 6mo f
295
QoL
257
QoL
5  LTF/WD
8 Died
10 LTF/WD
28 Died
10 WD after HF hospitalization
5 changed pacing mode
20 changed pacing mode
57 DAVID pa543 new patients
Primary prevention      n=393
Secondary prevention n=150
6 no co fu
Figure 1 Flow of Patients in the DAVID II Trial
The diagram depicts randomization of the DAVID II (Dual Chamber and VVI Implant
available for evaluation at 6-month follow-up and at study close-out. AAI-70  atria
lost to follow-up; QoL  quality of life assessment; R  randomized; VVI-40  venion), or voluntarily (2 relocated, 1 refused further follow- bp), and thus were not available for the final quality of life
ssessment.
acing. At 3-month follow-up, 7.5% of patients in the
AI-70 treatment arm received no atrial pacing, whereas
he frequency of atrial pacing ranged from 1% to 20% in
2.5% of patients, from 21% to 40% in 18%, and 40% in
2% of patients. By comparison, ventricular pacing was rare
n the VVI-40 group at 3-month follow-up; 13% of patients
eceived none, and the frequency of ventricular pacing
veraged 2% in the remainder. At 24-month follow-up,
he overall frequency of atrial pacing averaged 47% in the
AI-70 group, and ventricular pacing 2% in the VVI-40
roup. Heart rates (mean  SD) differed modestly between
AI-70 and VVI-40 groups at 3 and 24 months (72  8
eats/min vs. 66  13 beats/min, and 73  6 beats/min vs.
5  12 beats/min, respectively; p  0.001).
edications. Use of heart failure medications, statins, and
ntiarrhythmics was similar between treatment groups at
ospital discharge after study enrollment (Table 2), and
emained so during follow-up. At 24 months of follow-up,
ngiotensin-converting enzyme inhibitors or receptor
235
QoL
297
QoL
264
QoL
At closeout
June 6, 2007
ied
TF/WD
ied
F/WD
D after HF hospitalization
Average follow-up
All patients              2.7 years
Withdrawn patients 1.7 years
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changed pacing mode
changed pacing mode
s without prior clinical endpoint
ry prevention     n=22
ndary prevention n=35
June 2003-
February 2005
efibrillator II) trial patients, baseline evaluation, and the number of patients
g at 70 beats/min; co  close-out; fu  follow-up; HF  heart failure; LTF 
r back-up pacing at 40 beats/min; WD  withdrawn.u
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The DAVID II Trial March 10, 2009:872–80atients assigned to VVI-40 and AAI-70 pacing, diuretics
y 61% and 55% of these treatment groups, beta-blockers by
1% and 93%, digoxin by 28% and 30%, spironolactone by
6% and 17%, statins by 79% and 81%, and antiarrhythmic
edications by 22% of patients. Similarly, doses of beta-
lockers, angiotensin-converting enzyme inhibitors, and
ngiotensin receptor blockers did not significantly differ
etween treatment groups at study entry or during follow-
p, and were comparably titrated upward over time in both
reatment groups. At study entry, 68% of patients in the
VI-treatment arm versus 73% of those in the AAI-70
reatment arm were at 50% of targeted daily doses for
aseline Characteristics
Table 2 Baseline Characteristics
Overall
VVI-40 AAI-70
Number enrolled 300 300
Mean age, yrs 63 64
Male, % 85.3 84.7
Mean LVEF 26.6 26.3
Primary prevention, % 68.7 69.7
Clinical history before randomization, %
AF/flutter 15.3 13.0
MI 88.3 86.0
CHF 65.3 67.0
Hypertension 65.7 66.3
Diabetes mellitus 33.3 31.0
Ischemic cardiomyopathy, % 93.0 93.0
NYHA functional class, %
I 45.7 41.3
II 44.7 49.0
III 9.7 9.7
Discharge medications after enrollment, %
ACEI or ARB 87.7 90.0
Beta-blocker 90.3 88.0
Diuretic 56.7 56.7
Digoxin 27.0 31.3
Spironolactone 18.3 19.0
Statin 75.3 76.3
Antiarrhythmic medications 16.7 17.0
Baseline electrocardiogram available, n 296 292
Heart rate, mean (SD) 69 (13) 70 (14)
PR, mean (ms) (SD) 181 (33) 179 (39)
QRS, mean (ms) (SD) 110 (25) 111 (24)
First-degree AV block (PR 200 ms), % 21.3 20.2
Left bundle branch block, % 11.5 12.0
Right bundle branch block, % 4.7 5.5
Nonspecific intraventricular conduction defect, % 25.7 25.3
Baseline quality of life available, n 295 297
SF-36 physical score, mean (SD) 37 (10) 37 (11)
SF-36 mental score, mean (SD) 48 (11) 49 (10)
MLHF physical score, mean (SD) 18 (11) 17 (11)
MLHF emotional score, mean (SD) 9.0 (7.0) 8 (6)
AI-70  atrial pacing at 70 beats/min; ACEI  angiotensin-converting enzyme inhibitor; AF 
trial fibrillation; ARB  angiotensin receptor blocker; AV  atrioventricular; CHF  congestive
eart failure; LVEF  left ventricular ejection fraction; MI  myocardial infarction; MLHF 
innesota Living With Heart Failure Questionnaire; NYHA  New York Heart Association; SF-36 
hort Form-36 Health Survey; VVI-40  ventricular back-up pacing at 40 beats/min.ngiotensin-converting enzyme inhibitors and receptor rlockers, and 49% versus 52% of patients for beta-blockers;
t 24 months, the corresponding values were 78% versus
0% of patients for angiotensin-converting enzyme inhibi-
ors and receptor blockers, and 66% versus 69% of patients
or beta-blockers (p 0.001 compared with dosing levels of
hese drugs at study entry in each pacing arm).
rial termination. By the December 2006 meeting of the
ata Safety Monitoring Board, the test statistic had crossed
he boundary for rejection of the null hypothesis, with no
ifference in the primary outcome, but potentially contra-
ictory differences in quality of life measures. Accordingly,
he Board recommended continuing the study to obtain
dditional quality of life measures, for which the modified
hort Form-36 Health Survey physical questionnaire was
eveloped and study termination rescheduled to allow suf-
cient time for each patient to accrue at least 1 more
ollow-up before trial close-out. The average time of
ollow-up was 2.7 years (range 1 week to 4 years).
linical end points. There were no significant differences
etween the treatment arms in the primary combined end
oint of time to heart failure hospitalization or death, with
n overall incidence of 11.1%, 16.9%, and 24.6% at 1, 2, and
years, respectively (Fig. 2). Nor was any significant effect
bserved on the primary outcome that might be attributable
o the frequency of atrial pacing in the AAI-70 treatment
roup. There were also no differences observed between
reatment arms when time to death and heart failure
ospitalization were examined separately, nor among sub-
roups examined for implantable defibrillator indication,
ex, age, resting heart rate, ejection fraction, heart failure
istory, QRS duration or PR interval (Fig. 3). Similarly, the
ncidence of atrial fibrillation, syncope, (Fig. 4) or appro-
riate/inappropriate shocks (Fig. 5) did not differ between
acing groups.
uality of life. Baseline Short Form-36 Health Survey and
LHF summary scores are displayed in Table 2. Compar-
ng the changes from baseline to 6 months, the VVI-40
roup experienced a greater improvement in the Short
orm-36 Health Survey physical subscale, of 2.6 compared
ith 1.2 points for the AAI-70 group (p  0.04 after
djustment for baseline factors affecting the physical sub-
cale: age, heart failure history, diabetes mellitus, depres-
ion, and atrial fibrillation). The MLHF physical subscale
hanges also trended weakly in favor of VVI-40 pacing, an
mprovement of 4.0 versus 3.0 points (p  0.19). Modest
mprovements in the Short Form-36 Health Survey mental
ubscale (improvement of 1.2 points) and the MLHF
motional subscale (improvement of 2.0 points) were ob-
erved, but without significant differences between treat-
ent arms.
In contrast, responses to the Global Rating Change
ndicated an improved sense of health between 3 and 6
onths for the AAI-70 group compared with the VVI-40
roup. That is, 43% of the patients reporting worse health,
8% of those reporting the same health, and 57% of those
eporting better health were in the AAI arm (p  0.026).
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March 10, 2009:872–80 The DAVID II Trialorresponding proportions at the 3-month follow-up were
1%, 50%, and 49%. No differences were observed for
imple Outcome Screen measures between treatment
roups during follow-up.
At 6 months, the modified Short Form-36 Health Survey
hysical subscale was highly correlated with the 6-month
hort Form-36 Health Survey physical score (0.94), and
Number of Patients at Risk at Month Sh
0 18 36
VVI-40 300 252 109
AAI-70 300 251 109
0.5
0.4
0.3
0.2
0.1
0.0
0.5
0.4
0.3
0.2
0.1
0.0
0 18 36 0
Months from Randomization to Event Months from R
Death or First Hospitalization for 
New or Worsened Heart Failure
P = 0.95 P = 0.81
VVI-40
AAI-70
A
E
ve
n
t 
R
at
e
Figure 2 Primary Outcome
Event rates are depicted for the primary (composite) end point (left) and its comp
(AAI-70 [green lines]) and ventricular back-up pacing at 40 beats/min (VVI-40 [blu
the total number of deaths and number of patients hospitalized for heart failure in
2 3 4
Primary
Secondary
<= 65
> 65
Male
Female
< 70
>= 70
<= 35 
> 35
History of CHF
No history of CHF
Subgroups (Relative Risk and 95% CI)
Age (years)
Gender
Heart rate (bpm)
LVEF
CHF
Relative Risk
ICD indication
Favors AAI Favors VVI
OVERALL
Figure 3 Primary Outcome Depicted by Patient Subgroups
No differences favoring one or the other treatment arm were observed when
death and heart failure hospitalization were examined among the subgroups
shown. AAI  atrial pacing at a rate of 40 beats/min; bpm  beats/min; CHF
 congestive heart failure; CI  confidence interval; ICD  implantable cardio-
verter-defibrillator; LVEF  left ventricular ejection fraction; VVI  ventricular
back-up pacing at a rate of 40 beats/min.aas slightly improved in the VVI-40 cohort, but did not
ndicate any treatment effect when administered at study
lose-out.
iscussion
t the time the first DAVID trial was conducted, dual
hamber defibrillators were increasingly being implanted,
egardless of whether bradycardia pacing support was
eeded. In this climate of practice, the DAVID trial tested
he hypothesis that heart failure hospitalizations and mor-
ality would be reduced as a result of the more aggressive use
f heart failure medications afforded by active pacing or
erhaps because of the benefits resulting from pacing itself.
hat the outcome of the DAVID trial was unexpectedly
orse in the actively paced group did not necessarily
isprove this hypothesis. Rather, it is possible that the mode
f pacing chosen for the trial (DDDR-70) was merely the
rong mechanistic approach to achieve its ends, as sug-
ested by the growing appreciation of the ill effects from
ight ventricular pacing that the DAVID trial was largely
esponsible for initially bringing to clinical attention. The
AVID II trial tested this alternate mode hypothesis. As
uch, it examined the safety of atrial compared with minimal
entricular pacing in a population of implantable defibrilla-
or recipients who were comparable in their baseline char-
cteristics and in risk stratifiers associated with worse
utcome in the DAVID trial. No differences in the primary
ombined end point of time to heart failure hospitalization
r death were found between treatment arms. These find-
ngs were in significant contrast to those of the DAVID
rial, in which AV sequential pacing increased the risk of
eart failure hospitalization or death, but were insufficient to
uggest that atrial pacing, while as “safe,” offers any inherent
Deaths        Heart Failure Hospitalizations
36 47
38 47
Number of  End Point Events in Follow-up
36 36180
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0.0
ization to Event Months from Randomization to Event
Hospitalization for New or Worsened
Heart Failure
P = 1.0
VVI-40
VVI-40
AAI-70
(middle and right) in the 2 treatment groups: atrial pacing at 70 beats/min
]). The tables indicate the number of patients at risk by month of follow-up, and
treatment group.own
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The DAVID II Trial March 10, 2009:872–80inimizes pacing altogether. The DAVID II trial was
esigned to test for noninferiority, but, as in most studies of
00 patients, was not powered to conduct definitive sub-
roup analyses.
econdary end points. In addition to the primary end
oint, all secondary end points also failed to demonstrate
ifferences between the 2 pacing strategies. The incidence of
eath, heart failure hospitalization, atrial fibrillation, syn-
ope, first hospitalization, and appropriate and inappropri-
te shocks did not differ between randomized groups (Fig.
). There was a trend toward fewer inappropriate shocks in
he AAI-70 treatment arm, but that did not reach statistical
ignificance (Fig. 5).
trial fibrillation. The incidence of atrial fibrillation in the
AVID II study population was 13.7% at 3 years, which
hould have allowed for detecting substantial differences in
ts occurrence between treatment groups. In a previous trial,
trial pacing reduced the incidence of atrial fibrillation when
Figure 4 Secondary Outcomes
Event rates are shown for syncope (left), atrial fibrillation (middle), and first hospi
treatment group: atrial pacing at 70 beats/min (AAI-70 [green lines]) and ventricu
Figure 5 Appropriate and Inappropriate Shocks
Event rates are shown for appropriate shocks (left) and inappropriate shocks (righ
atrial pacing at 70 beats/min (AAI-70 [green lines]) and ventricular back-up pacingacemakers were implanted for sinus node dysfunction (13).
ailure to see a comparable effect in the DAVID II trial
ay be because atrial rate support improves atrial fibrilla-
ion rhythm control primarily when it prevents bradycar-
ia in predisposing conditions such as sick sinus syndrome.
t is also possible that the presence of significant left
entricular dysfunction in DAVID II trial patients dimin-
shed the beneficial effect of a more rapid atrial rate on the
ncidence of atrial fibrillation. Notably, a higher incidence of
trial fibrillation during cardiac resynchronization therapy
as recently associated with the frequency of right atrial
acing, indicating that a rhythm benefit from pacing is
ot necessarily a foregone conclusion in a heart failure
opulation (14).
yncope. Syncope was observed in equal frequency in both
reatment groups. This finding suggests that when such
ymptoms are attributable to bradycardia, neither atrial nor
VI pacing offers any inherent advantage. For example,
ion (right) for any cause in each
k-up pacing at 40 beats/min (VVI-40 [blue lines]).
ach treatment group:
beats/min (VVI-40 [blue lines]).talizat
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March 10, 2009:872–80 The DAVID II TrialVI-40 pacing may afford protection from asystole during
inus pauses, but may result in syncope from the slow
entricular rate and loss of AV synchrony. Conversely, atrial
acing prevents atrial asystole and enables AV synchrony,
ut the resulting ventricular rate is completely dependent
pon the integrity of intrinsic AV conduction. Because
atients enrolled in the DAVID II trial had no indication
or pacing, it is also possible that syncopal events of
radycardia etiology were uncommon during the study,
egardless of treatment assignment. Taken together, our
ata do not support the need for either mode of pacing for
rotection from syncope or atrial fibrillation in implantable
efibrillator recipients without the presence of other
ndications.
omparison with previous studies. Event rates were
ower in the DAVID II trial population than in the DAVID
rial; this finding was explainable by a shift in the demo-
raphics of enrolled patients. Primary prevention patients
omprised 69% of the DAVID II trial population, com-
ared with 49% in the DAVID trial; 87% of the patients
ad a history of myocardial infarction compared with 49%
n the DAVID trial. In addition, the qualifications for
rimary prevention ICDs changed between the trials. In the
AVID trial, eligible patients were required to undergo
lectrophysiologic testing with inducible ventricular tachy-
ardia, similar to the MADIT (Multicenter Automatic
efibrillator Implantation Trial) and MUSTT (Multicenter
nsustained Tachycardia Trial) study patients (1,15,16).
onversely, 60% of primary prevention patients in the
AVID II trial were enrolled without electrophysiologic
esting, in keeping with updated treatment guidelines based
n the MADIT II trial (17). Neither DAVID trial enrolled
rimary prevention patients with nonischemic cardiomyop-
thy (Table 2) (1).
In having achieved relatively frequent atrial pacing with-
ut major changes in heart rate (which averaged only 6 to 8
eats/min), the DAVID II trial suggests that the deleterious
ffects of DDDR-70 pacing observed in the DAVID trial
ere not the consequence of atrial pacing itself, as this
ould have also resulted in worse outcomes in the current
tudy. Rather, DDDR-70 pacing probably accounted for
he worse outcomes due to unnecessary RV pacing in a
usceptible population. This observation is in keeping with
he recent retrospective analysis of the DAVID and
ADIT II trial data, suggesting such an explanation was
he most likely cause for their increased incidence of death
nd heart failure hospitalization (18,19).
The results of the DAVID II trial are similar to those of
he recently published INTRINSIC RV trial (20). As in our
rial, no significant differences were found in the combined
rimary end point between a dual chamber pacing mode
hat used an algorithm to minimize ventricular pacing,
ompared with backup pacing (VVI-40). However, the
AVID II trial comprised sicker patients, with a higher
ncidence of heart failure (66% vs. 37%), coronary artery
isease (93% vs. 67%), and a higher event rate in its control Troup (11.1% vs. 9.5%). Furthermore, the frequency of
ither right atrial or right ventricular pacing in the DDDR
rm of the INTRINSIC (Inhibition of Unnecessary RV
acing With AVSH in ICDs Study) trial was low (averag-
ng only 13%), arguably resulting in its having only com-
ared 2 minimally paced treatment groups. In contrast, the
igher prevalence of atrial pacing (averaging 47%) in the
AI-70 arm of the DAVID II trial affords a truer compar-
son between more frequent atrial pacing and minimal
acing (VVI-40). Taken together, the results of these 2
tudies suggest that atrial pacing, of whatever frequency, is
s safe as the avoidance of pacing in a heterogeneous group
f implantable defibrillator recipients.
uality of life. The conflicting quality of life observations
t 6 months in the DAVID II trial likely reflect chance
ariation. This chance variation was exemplified by Global
ating Change responses that did not differ between treat-
ent arms at 3 months and by Global Rating Change and
hort Form-36 Health Survey physical responses that dif-
ered significantly between treatment arms at 6 months, but
n opposite directions; and it was confirmed by the modified
hort Form-36 Health Survey physical score, which mim-
cked the Short Form-36 Health Survey score at baseline
nd 6 months, but showed no difference at close-out
etween treatment arms.
tudy limitations. Limitations of the DAVID II trial
nclude those that are inherent to a noninferiority study.
lthough the sample size was sufficiently large to reject the
ull hypothesis, our alternative hypothesis (that the effect of
AI-70 on the combined end point was no worse than
VI-40 backup pacing) could be compromised by the rate
f patients who changed pacing assignment, or missing data
rom those withdrawn or lost to follow-up. The rate of such
vents was low and was similar in both treatment arms (Fig. 1).
urthermore, the average interval before withdrawal or loss to
ollow-up was 1.7 years, such that substantial information
bout treatment course was still derived in such instances.
This study did not specifically address effects of more
apid heart rates or rate-responsive pacing, which invite
urther study. Moreover, it did not address the differential
isks from implantation and long-term morbidity between
ingle and dual chamber defibrillators, as all patients re-
eived only the latter. Nor did it address the effect of more
requent (AAI-70) pacing on implantable defibrillator gen-
rator life, and whether potentially offset by other battery
avings (such as the trend toward fewer inappropriate
hocks). The frequency of shocks was also not a primary
tudy end point, and could have been influenced by factors
ther than pacing mode. In addition, the study addressed
atients who had no clinical indication for permanent
acing, and therefore cannot be extrapolated to those with
acing indications. The DAVID II trial included a small
umber of patients who were originally included in the
VI-40 arm of the DAVID trial and subsequently re-
andomized to the treatment arms of the DAVID II trial.
he inclusion or exclusion of these patients did not alter the
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The DAVID II Trial March 10, 2009:872–80esults presented. Finally, it could be argued that titration of
eart failure medications was not sufficiently aggressive to
ccentuate the potential differences between pacing modes
hat might otherwise have been observed, particularly
mong recipients of atrial pacing. However, the dosing
evels achieved with heart failure medications compare well
ith those targeted in heart failure patients and conformed
o published guidelines. Our results suggest that active
acing is not necessarily required to attain adequate dosing
evels of such medications.
onclusions
mong implantable defibrillator recipients with left ventric-
lar dysfunction and no clinical indications for pacing, the
ffect of atrial pacing on event-free survival and quality of
ife was not substantially worse than, and was likely equiv-
lent to, backup-only ventricular pacing. Atrial pacing may
e considered a “safe alternative” when pacing is desired, but
ffords no clear advantage or disadvantage over a ventricular
acing mode that minimizes pacing altogether.
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APPENDIX
or a list of the DAVID II principal investigators and
oordinators, please see the online version of this article.
